593-P: Effectiveness of Digital Therapeutics to Improve Clinical Outcomes in Patients with Type 2 Diabetes Mellitus on Insulin Therapy

Abstract

Background: Diabetes self-management education and support (DSMES) is integral towards maintaining continuity of care between physician visits especially for patients on insulin therapy to facilitate healthy coping. The present study explores the usage patterns and real-world effectiveness of the Wellthy CARE™ digital therapeutic (WDTx) platform in achieving glycemic control among patients with type 2 diabetes mellitus (T2DM) on insulin therapy. Methods: The WDTx platform consists of a smartphone application with a 52-week program to provide DSMES through self-monitoring of blood glucose, access to evidence-based content regarding insulin usage and remote guidance by a health coach to enable lifestyle modifications and healthy coping. All app interactions were analyzed at baseline and during the program to determine factors driving patient engagement and clinical outcomes. Results: Study participants (n=106) had a mean age of 51.4 years (SD 14.0 years) and consisted of 39 females (36.8%). Overall, a significant mean decrease in average blood sugar (ABS) by 29.9 mg/dl (95%CI 16.6-43.3 mg/dl, P<0.001) was observed with a 31.9% reduction in proportion of hypoglycemia logs and an average of 6.1 app interactions per patient per week on the platform thus proving continuity of care provided through WDTx. Users in the highest tertile for early app interactions (within week 1) demonstrated a significant mean decrease in ABS by 30.8 mg/dl (95%CI 7.5-54.0 mg/dl, P<0.01) while no significant change was seen in the corresponding lowest tertile. Over the entire program, users in the tertile with highest app engagement showed a significant mean decrease in ABS of 27.4 mg/dl (95%CI 8.8-46.1 mg/dl, P<0.01) as compared to no significant change in the lowest tertile. Conclusion: This study thus demonstrates the effectiveness of the WDTx platform to impart critical DSMES, maintain continuity of care and improve clinical outcomes in patients with T2DM on insulin therapy. Disclosure R. R. Adhikary: Employee; Self; Wellthy Therapeutics Pvt Ltd. S. Kolwankar: Employee; Self; Wellthy Therapeutics Pvt Ltd. R. Verma: Consultant; Self; Wellthy Therapeutics Pvt Ltd. J. Bhatt: Employee; Self; Wellthy Therapeutics Pvt Ltd. K. L. Pakhale: None. R. Sahay: Advisory Panel; Self; Cipla Inc., USV Private Limited, Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk Pharma Ltd.